7 results about "Normal aging" patented technology

The invention discloses an application of a substance taking Angpt18 as a target in preparation of a medicine for treating and delaying senescence, and the key regulation effect of an Angpt18 gene in the occurrence and progression process of normal senescence and senescence-related diseases is found for the first time through systematic and in-depth research; further experiments prove that by inhibiting or down-regulating the expression of the Angpt18 gene, the senescence process can be obviously delayed, and the expressions such as hypomnesia and behavioral ability decline in the senescence process can be effectively improved. Therefore, the Angpt18 gene can be used as an important intervention target for senescence and related diseases thereof, can be used for developing drugs with senescence delaying or treatment effects, can also be used as a biomarker for evaluating the senescence degree and diagnosing and prognosing the related diseases of senescence, and has wide application prospects and clinical transformation values.

Described herein are pharmaceutical compositions and methods for treating, detecting, characterizing, and reducing misfolding proteins and preventing related diseases such as neurodegenerative diseases and normal aging.

The invention belongs to the technical field of kidney aging assessment, and particularly relates to a kidney aging clock assessment method based on kidney pathology and artificial intelligence. According to the kidney aging evaluation method, the kidney aging degree can be evaluated more accurately by analyzing the pathological characteristics related to kidney aging and calculating the correlation weight, the aging clock score is generated, the kidney aging process is quantified, and the kidney aging evaluation accuracy is improved by monitoring the aging clock score of the kidney in real time and optimizing the evaluation period length according to the allowable deviation score. The kidney senescence state can be found in time, in the normal senescence state, the evaluation period can be adjusted in time, the kidney senescence evaluation efficiency can be improved, in the abnormal senescence state, a corresponding response mechanism can be triggered, it is ensured that measures can be taken rapidly in the abnormal senescence state, and the kidney senescence evaluation efficiency is improved. Therefore, corresponding data support can be provided for clinical diagnosis and treatment.

New treatments using Clopidogrel, Ticagrelor, Prasugrel, and / or Cangrelor and new uses for Clopidogrel are disclosed herein. For example, it has been found that conditions such as ALS (Amyotrophic Lateral Sclerosis), Alzheimer's Disease, the normal aging process, nerve damages, nerve injuries, muscular dystrophy, strenuous physical activities, fatigue, and other conditions that affect synapses as well as skeletal muscles can be treated using Clopidogrel or pharmaceutically acceptable other forms. New mechanisms and modes of action are explained herein.

Embodiments of the instant disclosure relate to early diagnosis and intervention and / or treatment of neurodegenerative disorders and / or brain damage due to normal aging. Certain embodiments disclosed herein relate to quantifying concentrations of ubiquitin c-terminal hydrolase L1 (UCH-L1) in samples obtained from a subject to assess neuronal cell health and / or diagnose the subject with age-related neuronal cell damage. In some embodiments, a subject can be treated with an effective amount of a therapeutic to stabilize and / or reduce concentrations of UCH-L1 in the subject and treat the subject. In other embodiment, a targeted therapeutic agent, process, or task can be assessed for efficacy of reversing brain aging in a subject.

Provided is an application of a BAZ2B gene as a target in slowing aging. It is disclosed that the BAZ2B gene plays an important regulatory role in occurrence and development of normal aging and age-related diseases, and the down-regulation thereof can significantly slow aging and alleviatememory decay, capacity degradation and the like in the aging process. The BAZ2B can be used as the research target of aging and age-related diseases for developing drugs of inhibiting or delaying aging, and used as a diagnostic and prognostic marker of aging and age-related diseases.

This application discloses an intelligent monitoring method and system for the status of medical devices based on the Internet of Things (IoT), relating to the field of medical device monitoring. First, it utilizes information such as the device's service life and operating conditions to train a unique aging model for each device, predicting its normal performance parameters at the current stage of its life cycle. Then, by subtracting this predicted normal aging value from the real-time monitoring data, a clean residual signal is obtained. Subsequent anomaly detection will only target this residual signal; any significant fluctuations will likely point to an impending abnormal failure. This prediction-subtraction-detection model fundamentally solves the problem of aliasing between normal aging and abnormal deviations in data characteristics and adapts to the individual differences of devices, thereby accurately identifying true impending failures and significantly reducing the false alarm rate.